Is CD69 an effective brake to control inflammatory diseases?

Trends in Molecular Medicine

Volumn 19, Issue 10, 2013, Pages 625-632

  González Amaro, Roberto ^a   Cortés, José R ^b   Sánchez Madrid, Francisco ^b,c   Martín, Pilar ^b  

^a UNIVERSIDAD AUTÓNOMA DE SAN LUIS POTOSÍ   (Mexico)

^b CENTRO NACIONAL DE INVESTIGACIONES CARDIOVASCULARES CNIC   (Spain)

^c UNIVERSIDAD AUTÓNOMA DE MADRID   (Spain)

Author keywords

CD69; Immunoregulation; Inflammatory diseases; Th17 lymphocytes; Treg lymphocytes

Indexed keywords

CD69 ANTIGEN;

ALLERGY; DISEASE PREDISPOSITION; HUMAN; IMMUNE RESPONSE; IMMUNOCOMPETENT CELL; IMMUNOREGULATION; INFLAMMATION; NONHUMAN; REGULATORY T LYMPHOCYTE; REVIEW; TH17 CELL;

MUS;

CD69; IMMUNOREGULATION; INFLAMMATORY DISEASES; TH17 LYMPHOCYTES; TREG LYMPHOCYTES;

ANIMALS; ANTIGENS, CD; ANTIGENS, DIFFERENTIATION, T-LYMPHOCYTE; AUTOIMMUNE DISEASES; HUMANS; HYPERSENSITIVITY; IMMUNOMODULATION; INFLAMMATION; LECTINS, C-TYPE; T-LYMPHOCYTES, REGULATORY;

EID: 84884815357     PISSN: 14714914     EISSN: 1471499X     Source Type: Journal    
DOI: 10.1016/j.molmed.2013.07.006     Document Type: Review

References (77)

1. Sancho D., et al. CD69 is an immunoregulatory molecule induced following activation. Trends Immunol. 2005, 26:136-140.
2. Cebrian M., et al. Triggering of T cell proliferation through AIM, an activation inducer molecule expressed on activated human lymphocytes. J. Exp. Med. 1988, 168:1621-1637.
3. Testi R., et al. T cell activation via Leu-23 (CD69). J. Immunol. 1989, 143:1123-1128.
4. Martin P., et al. CD69 association with Jak3/Stat5 proteins regulates Th17 cell differentiation. Mol. Cell. Biol. 2010, 30:4877-4889.
5. Shinoda K.E.A. Type II membrane protein CD69 regulates the formation of resting T-helper memory. Proc. Natl. Acad. Sci. U.S.A. 2012, 109:7409-7414.
6. Alari-Pahissa E., et al. CD69 does not affect the extent of T cell priming. PLoS ONE 2012, 7:e48593.
7. + regulatory T cells following adoptive transfer. Eur. J. Immunol. 2012, 42:1429-1435.
8. Shiow L.R., et al. CD69 acts downstream of interferon-α/β to inhibit S1P1 and lymphocyte egress from lymphoid organs. Nature 2006, 440:540-544.
9. Lamana A., et al. CD69 modulates sphingosine-1-phosphate-induced migration of skin dendritic cells. J. Invest. Dermatol. 2011, 131:1503-1512.
10. Sancho D., et al. CD69 downregulates autoimmune reactivity through active transforming growth factor-β production in collagen-induced arthritis. J. Clin. Invest. 2003, 112:872-882.
11. Martin P., et al. The leukocyte activation antigen CD69 limits allergic asthma and skin contact hypersensitivity. J. Allergy Clin. Immunol. 2010, 126:355-365.
12. Cruz-Adalia A., et al. CD69 limits the severity of cardiomyopathy after autoimmune myocarditis. Circulation 2010, 122:1396-1404.
13. Radulovic K., et al. CD69 regulates type I IFN-induced tolerogenic signals to mucosal CD4 T cells that attenuate their colitogenic potential. J. Immunol. 2012, 188:2001-2013.
14. Gomez M., et al. Atherosclerosis development in apolipoprotein E-null mice deficient for CD69. Cardiovasc. Res. 2009, 81:197-205.
15. Khallou-Laschet J., et al. The proatherogenic role of T cells requires cell division and is dependent on the stage of the disease. Arterioscler. Thromb. Vasc. Biol. 2006, 26:353-358.
16. Murata K., et al. CD69-null mice protected from arthritis induced with anti-type II collagen antibodies. Int. Immunol. 2003, 15:987-992.
17. Miki-Hosokawa T., et al. CD69 controls the pathogenesis of allergic airway inflammation. J. Immunol. 2009, 183:8203-8215.
18. Yamauchi K., et al. Attenuation of lung inflammation and fibrosis in CD69-deficient mice after intratracheal bleomycin. Respir. Res. 2011, 12:131.
19. Tsuyusaki J., et al. Cigarette smoke-induced pulmonary inflammation is attenuated in CD69-deficient mice. J. Recept. Signal. Transduct. Res. 2011, 31:434-439.
20. Lamana A., et al. The role of CD69 in acute neutrophil-mediated inflammation. Eur. J. Immunol. 2006, 36:2632-2638.
21. Laffon A., et al. Upregulated expression and function of VLA-4 fibronectin receptors on human activated T cells in rheumatoid arthritis. J. Clin. Invest. 1991, 88:546-552.
22. + T lymphocytes in viral chronic active hepatitis. Gastroenterology 1990, 98:1029-1035.
23. Afeltra A., et al. Expression of CD69 antigen on synovial fluid T cells in patients with rheumatoid arthritis and other chronic synovitis. Ann. Rheum. Dis. 1993, 52:457-460.
24. Afeltra A., et al. Coexpression of CD69 and HLADR activation markers on synovial fluid T lymphocytes of patients affected by rheumatoid arthritis: a three-colour cytometric analysis. Int. J. Exp. Pathol. 1997, 78:331-336.
25. Gonzalez-Alvaro I., et al. Interleukin-15 and interferon-γ participate in the cross-talk between natural killer and monocytic cells required for tumour necrosis factor production. Arthritis Res. Ther. 2006, 8:R88.
26. Rollin R., et al. Early lymphocyte activation in the synovial microenvironment in patients with osteoarthritis: comparison with rheumatoid arthritis patients and healthy controls. Rheumatol. Int. 2008, 28:757-764.
27. Kalogerou A., et al. Early T cell activation in the skin from patients with systemic sclerosis. Ann. Rheum. Dis. 2005, 64:1233-1235.
28. Radstake T.R., et al. The pronounced Th17 profile in systemic sclerosis (SSc) together with intracellular expression of TGFβ and IFNγ distinguishes SSc phenotypes. PLoS ONE 2009, 4:e5903.
29. Varga J., Whitfield M.L. Transforming growth factor-β in systemic sclerosis (scleroderma). Front. Biosci. (Schol. Ed.) 2009, 1:226-235.
30. Hervier B., et al. Phenotype and function of natural killer cells in systemic lupus erythematosus: excess interferon-γ production in patients with active disease. Arthritis Rheum. 2011, 63:1698-1706.
31. Rus V., et al. Increased expression and release of functional tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) by T cells from lupus patients with active disease. Clin. Immunol. 2005, 117:48-56.
32. Yu X., et al. Anti-CD69 autoantibodies cross-react with low density lipoprotein receptor-related protein 2 in systemic autoimmune diseases. J. Immunol. 2001, 166:1360-1369.
33. Ooka S., et al. Autoantibodies to low-density-lipoprotein-receptor-related protein 2 (LRP2) in systemic autoimmune diseases. Arthritis Res. Ther. 2003, 5:R174-R180.
34. + in patients with multiple sclerosis. Eur. Neurol. 1993, 33:152-155.
35. Lunemann J.D., et al. Cross-sectional and longitudinal analysis of myelin-reactive T cells in patients with multiple sclerosis. J. Neurol. 2004, 251:1111-1120.
36. Matsuya N., et al. Increased T-cell immunity against aquaporin-4 and proteolipid protein in neuromyelitis optica. Int. Immunol. 2011, 23:565-573.
37. Song F., et al. The Peyer's patch is a critical immunoregulatory site for mucosal tolerance in experimental autoimmune encephalomylelitis (EAE). J. Autoimmun. 2008, 30:230-237.
38. Brucklacher-Waldert V., et al. Phenotypical and functional characterization of T helper 17 cells in multiple sclerosis. Brain 2009, 132:3329-3341.
39. Gessl A., Waldhausl W. Elevated CD69 expression on naive peripheral blood T-cells in hyperthyroid Graves' disease and autoimmune thyroiditis: discordant effect of methimazole on HLA-DR and CD69. Clin. Immunol. Immunopathol. 1998, 87:168-175.
40. Marazuela M., et al. Adhesion molecules from the LFA-1/ICAM-1,3 and VLA-4/VCAM-1 pathways on T lymphocytes and vascular endothelium in Graves' and Hashimoto's thyroid glands. Eur. J. Immunol. 1994, 24:2483-2490.
41. Marazuela M., et al. Regulatory T cells in human autoimmune thyroid disease. J. Clin. Endocrinol. Metab. 2006, 91:3639-3646.
42. Abdulahad W.H., et al. Skewed distribution of Th17 lymphocytes in patients with Wegener's granulomatosis in remission. Arthritis Rheum. 2008, 58:2196-2205.
43. Wahlstrom J., et al. Phenotypic analysis of lymphocytes and monocytes/macrophages in peripheral blood and bronchoalveolar lavage fluid from patients with pulmonary sarcoidosis. Thorax 1999, 54:339-346.
44. +CD28(null) cells?. Clin. Exp. Immunol. 2010, 160:256-265.
45. + T-cell activation is correlated with FEV1 in smokers. Respir. Med. 2006, 100:1088-1093.
46. Ekberg-Jansson A., et al. The expression of lymphocyte surface antigens in bronchial biopsies, bronchoalveolar lavage cells and blood cells in healthy smoking and never-smoking men, 60 years old. Respir. Med. 2000, 94:264-272.
47. Hosono M., et al. Increased expression of T cell activation markers (CD25, CD26, CD40L and CD69) in atherectomy specimens of patients with unstable angina and acute myocardial infarction. Atherosclerosis 2003, 168:73-80.
48. - T cells, a new subset of regulatory T cells, suppress T cell proliferation through membrane-bound TGF-β1. J. Immunol. 2009, 182:111-120.
49. Kusdra L., et al. Changes in monocyte/macrophage neurotoxicity in the era of HAART: implications for HIV-associated dementia. AIDS 2002, 16:31-38.
50. Creemers P., et al. Evaluation of peripheral blood CD4 and CD8 lymphocyte subsets, CD69 expression and histologic rejection grade as diagnostic markers for the presence of cardiac allograft rejection. Transpl. Immunol. 2002, 10:285-292.
51. Posselt A.M., et al. CD69 expression on peripheral CD8 T cells correlates with acute rejection in renal transplant recipients. Transplantation 2003, 76:190-195.
52. Sagoo P., et al. Human regulatory T cells with alloantigen specificity are more potent inhibitors of alloimmune skin graft damage than polyclonal regulatory T cells. Sci. Transl. Med. 2011, 3:83ra42.
53. Alvarez C.M., et al. Kidney transplant patients with long-term graft survival have altered expression of molecules associated with T-cell activation. Transplantation 2004, 78:1541-1547.
54. Hartnell A., et al. CD69 is expressed by human eosinophils activated in vivo in asthma and in vitro by cytokines. Immunology 1993, 80:281-286.
55. Julius P., et al. CD69 surface expression on human lung eosinophils after segmental allergen provocation. Eur. Respir. J. 1999, 13:1253-1259.
56. Toma T., et al. Expansion of activated eosinophils in infants with severe atopic dermatitis. Pediatr. Int. 2005, 47:32-38.
57. Lourenco O., et al. T cells in sputum of asthmatic patients are activated independently of disease severity or control. Allergol. Immunopathol. (Madr.) 2009, 37:285-292.
58. Werfel T., et al. Rapid expression of the CD69 antigen on T cells and natural killer cells upon antigenic stimulation of peripheral blood mononuclear cell suspensions. Allergy 1997, 52:465-469.
59. Thunberg S., et al. Allergen provocation increases TH2-cytokines and FOXP3 expression in the asthmatic lung. Allergy 2010, 65:311-318.
60. Gandhi R., et al. Cutting edge: human latency-associated peptide + T cells: a novel regulatory T cell subset. J. Immunol. 2010, 184:4620-4624.
61. Bonelli M., et al. Quantitative and qualitative deficiencies of regulatory T cells in patients with systemic lupus erythematosus (SLE). Int. Immunol. 2008, 20:861-868.
62. Alvarado-Sanchez B., et al. Regulatory T cells in patients with systemic lupus erythematosus. J. Autoimmun. 2006, 27:110-118.
63. - T cells in patients with hepatocellular carcinoma are associated with tumor progression. J. Gastroenterol. Hepatol. 2011, 26:1519-1526.
64. Garcia-Hernandez M.H., et al. Regulatory T cells in children with intestinal parasite infection. Parasite Immunol. 2009, 31:597-603.
65. Vega-Ramos J., et al. CD69 limits early inflammatory diseases associated with immune response to Listeria monocytogenes infection. Immunol. Cell Biol. 2010, 88:707-715.
66. + T cells expressing early activation antigen CD69 in murine lupus: possible abnormal regulatory role for cytokine imbalance. J. Immunol. 1998, 161:1267-1273.
67. Martin-Gayo E., et al. Plasmacytoid dendritic cells resident in human thymus drive natural Treg cell development. Blood 2010, 115:5366-5375.
68. Saldanha-Araujo F., et al. Mesenchymal stem cells promote the sustained expression of CD69 on activated T lymphocytes: roles of canonical and non-canonical NF-κB signalling. J. Cell. Mol. Med. 2012, 16:1232-1244.
69. de Araujo F.F., et al. Regulatory T cells phenotype in different clinical forms of Chagas' disease. PLoS Negl. Trop. Dis. 2011, 5:e992.
70. Radstake T.R., et al. Increased frequency and compromised function of T regulatory cells in systemic sclerosis (SSc) is related to a diminished CD69 and TGFβ expression. PLoS ONE 2009, 4:e5981.
71. Rueda B., et al. Investigation of CD69 as a new candidate gene for rheumatoid arthritis. Tissue Antigens 2008, 72:206-210.
72. Gershon R.K., et al. Suppressor T cells. J. Immunol. 1972, 108:586-590.
73. Green D.R., Webb D.R. Saying the 'S' word in public. Immunol. Today 1993, 14:523-525.
74. Sakaguchi S., et al. Immunologic self-tolerance maintained by activated T cells expressing IL-2 receptor α-chains (CD25). Breakdown of a single mechanism of self-tolerance causes various autoimmune diseases. J. Immunol. 1995, 155:1151-1164.
75. + regulatory T cells: their knowns and unknowns. Immunol. Cell Biol. 2011, 89:346-351.
76. Weiner H.L., et al. Oral tolerance. Immunol. Rev. 2011, 241:241-259.
77. Collison L.W., et al. IL-35-mediated induction of a potent regulatory T cell population. Nat. Immunol. 2010, 11:1093-1101.